Prognomix offers a diagnostic and predictive technology for personalized medicine targeting type 2 diabetic subjects by using genomic signatures

Prognomix currently has under development four products, all indicated for use in diabetes (T2D) patients:

  Current Stage
Products Research Proof of
Concept		 Optimization Qualification Market
PGx IR01 progress progress progress
2012 1
PGx GR01 progress progress progress progress
2011 2
PGx CD01 progress progress
PGx IR02 progress

1. Laboratory Developed Test (CLIA) and IVDMIA in 2012

2. Contract with Pharmaceutical companies should occur as early as 2010

Information about each product is available on our Products page.